http://www.fpnotebook.com/
TiotropiumAka: Spiriva, Long-acting Anticholinergic Bronchodilator
- Indication
- Chronic Obstructive Pulmonary Disease (COPD)
- Mechanism
- Long-acting anticholinergic Bronchodilator
- Dosing
- Inhale one 18 mcg dose once daily
- Precautions
- Avoid use of Spiriva with Atrovent or Combivent due to minimal added benefit
- Use Albuterol MDI as short acting rescue medication instead of short acting Ipratropium
- Exception: May use Atrovent or combivent while starting spiriva in first 8-10 days
- Advantages
- Improves mean FEV1, Dyspnea and quality of life
- Decreased COPD exacerbations and hospitalizations
- More effective than Ipratropium Bromide in COPD
- At least as effective as Salmeterol in COPD
- Better compliance due to once daily dosing
- Disadvantages
- Expensive: $117 per month
- May cause Dry Mouth
- Adverse Effects
- Serious adverse effects
- Angioedema or other Hypersensitivity Reaction
- Paradoxical bronchospasm
- Glaucoma exacerbation
- Cerebrovascular Accident
- Initial report suggests risk as high as 2 cases per 1000 patients per year
- Confirmatory studies required and patients may continue on Spiriva currently
- (2008) Prescriber's Letter 15(4):21
- Common adverse effects
- Anticholinergic effects (e.g. blurred vision, Constipation, Dry Mouth, Urinary Retention)
- Gastrointestinal upset (e.g. Abdominal Pain, Dyspepsia)
- Rhinorrhea or Epistaxis
- References
- Panning (2003) Pharmacotherapy 23:183
- Hutton (2004) Am Fam Physician 69(12):2901
|
|---|
| Concepts | Organic Chemical (T109)
, Pharmacologic Substance (T121)
|
| English | tiotropium |
| Spanish | tiotropio |
| Credits | Derived from the NIH UMLS (Unified Medical Language System)
|
Navigation Tree